Total Baseline Tumor Size Predicts Survival Among Patients with Advanced Small-cell Lung Cancer Receiving Chemotherapy Plus Programmed Death-ligand 1 Inhibitor As First-line Therapy: a Multicenter Retrospective Observational Study

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Nov 19

PMID 39558947

Authors

Anna Tanaka

Shuhei Teranishi

Yukihito Kajita

Tomofumi Hirose

Ayami Kaneko

Yu Sairenji

Hidetoshi Kawashima

Kentaro Yumoto

Toshinori Tsukahara

Kenji Miura

Nobuaki Kobayashi

Masaki Yamamoto

Ryuichi Nishihira

Makoto Kudo

Naoki Miyazawa

Masanori Nishikawa

Takeshi Kaneko

Affiliations

Soon will be listed here.

Abstract

Introduction: Total baseline tumor size (BTS) is a prognostic factor for programmed death 1 and programmed death-ligand 1 (PD-L1) inhibitor treatments. However, the prognostic value of total BTS for patients with small-cell lung cancer (SCLC) who receive chemotherapy plus PD-L1 inhibitor remains unknown. Thus, in this study, we aimed to determine whether total BTS is associated with prognosis in patients with SCLC who receive chemotherapy plus PD-L1 inhibitor as first-line therapy.

Methods: This study included patients with extensive-stage SCLC or post-chemoradiotherapy recurrence of limited-stage SCLC who received chemotherapy plus PD-L1 inhibitor as first-line therapy from August 2019 to December 2022. The two lesions with the largest diameter among the measurable lesions in each organ were selected from up to five organs (maximum of 10 lesions), and the sum of all diameters was defined as total BTS. The patients were divided into two groups, large or small, with total BTS using X-tile software. Median survival was analyzed using the Kaplan-Meier method, and the groups were compared using the log-rank test. Univariate and multivariate analyses examined the association between total BTS and prognosis.

Results: Fifty patients were included; 14% had large total BTS (>183.2 mm) and 86% had small total BTS (≤183.2 mm). The median observation period was 10.5 months. The large total BTS group showed significantly worse overall survival than the small total BTS group (median: 26.8 months vs. 5.7 months, = 0.0003). The multivariate analysis indicated that large total BTS was an independent negative predictor of overall survival (hazard ratio: 7.14, 95% confidence interval: 1.89-26.96).

Discussion: Total BTS is a potentially useful prognostic factor for patients with advanced SCLC who receive chemotherapy plus PD-L1 inhibitor as first-line therapy.

References

Gungabeesoon J, Gort-Freitas N, Kiss M, Bolli E, Messemaker M, Siwicki M . A neutrophil response linked to tumor control in immunotherapy. Cell. 2023; 186(7):1448-1464.e20. PMC: 10132778. DOI: 10.1016/j.cell.2023.02.032. View

Masubuchi K, Imai H, Wasamoto S, Tsuda T, Minemura H, Nagai Y . Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival. Thorac Cancer. 2022; 13(19):2776-2785. PMC: 9527159. DOI: 10.1111/1759-7714.14621. View

Masucci M, Minopoli M, Carriero M . Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy. Front Oncol. 2019; 9:1146. PMC: 6874146. DOI: 10.3389/fonc.2019.01146. View

Suzuki S, Haratani K, Hayashi H, Chiba Y, Tanizaki J, Kato R . Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer. Eur J Cancer. 2021; 161:44-54. DOI: 10.1016/j.ejca.2021.11.011. View

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Liu S, Reck M, Mansfield A, Mok T, Scherpereel A, Reinmuth N . Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021; 39(6):619-630. PMC: 8078320. DOI: 10.1200/JCO.20.01055. View

Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Harada T . Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum-Etoposide Chemotherapy. Drugs Aging. 2023; 40(6):563-571. DOI: 10.1007/s40266-023-01034-4. View

Schabath M, Nguyen A, Wilson P, Sommerer K, Thompson Z, Chiappori A . Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients. Lung Cancer. 2014; 86(1):14-21. PMC: 4171454. DOI: 10.1016/j.lungcan.2014.07.014. View

Antonia S, Lopez-Martin J, Bendell J, Ott P, Taylor M, Eder J . Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016; 17(7):883-895. DOI: 10.1016/S1470-2045(16)30098-5. View

10.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

11.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

12.

Gooden M, de Bock G, Leffers N, Daemen T, Nijman H . The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011; 105(1):93-103. PMC: 3137407. DOI: 10.1038/bjc.2011.189. View

13.

Wang Y, Mathai J, Alamgeer M, Parakh S, Paul E, Mitchell P . Real-World Analysis of Clinical Characteristics and Survival Outcomes in Patients With Extensive-Stage SCLC Treated With First-Line Chemoimmunotherapy. JTO Clin Res Rep. 2023; 4(8):100544. PMC: 10388193. DOI: 10.1016/j.jtocrr.2023.100544. View

14.

Gay C, Stewart C, Park E, Diao L, Groves S, Heeke S . Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021; 39(3):346-360.e7. PMC: 8143037. DOI: 10.1016/j.ccell.2020.12.014. View

15.

Yao Y, Li B, Song R, Yang L, Zou B, Wang L . Efficacy and safety of thoracic radiotherapy in extensive-stage small-cell lung cancer patients receiving first-line immunotherapy plus chemotherapy: a propensity score matched multicentre retrospective analysis. Radiat Oncol. 2024; 19(1):25. PMC: 10900720. DOI: 10.1186/s13014-024-02420-x. View

16.

Zhu Y, Knolhoff B, Meyer M, Nywening T, West B, Luo J . CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014; 74(18):5057-69. PMC: 4182950. DOI: 10.1158/0008-5472.CAN-13-3723. View

17.

Zhang N, Jiang J, Tang S, Sun G . Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis. Int Immunopharmacol. 2020; 85:106677. DOI: 10.1016/j.intimp.2020.106677. View

18.

Xie J, Chen M, Han H, Xu K, Qiu G, Lin X . Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study. Thorac Cancer. 2023; 14(15):1327-1338. PMC: 10212658. DOI: 10.1111/1759-7714.14874. View

19.

Joseph R, Elassaiss-Schaap J, Kefford R, Hwu W, Wolchok J, Joshua A . Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clin Cancer Res. 2018; 24(20):4960-4967. PMC: 6916264. DOI: 10.1158/1078-0432.CCR-17-2386. View

20.

Qi W, Xiang Y, Zhao S, Chen J . Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab. Cancer Immunol Immunother. 2021; 70(11):3199-3206. PMC: 10991671. DOI: 10.1007/s00262-021-02926-3. View